Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Ridgeback Biotherapeutics by Year
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Net R&D cost-sharing expense ($M) ($M)
Merck Ridgeback Biotherapeutics: $31M in FY2025, up 138.5% from a year earlier.
Latest, FY2025
31
Period ended Dec 31, 2025
Change on a year earlier
+138.5%
13 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Net R&D cost-sharing expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31 | +138.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 13 | -78.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 60 | -31.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 88 | -35.8% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 137 | -60.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 349 | – | Form 10-K (filed 2023-02-24) ↗ |
Cite this data
StockData. (2026). Merck Ridgeback Biotherapeutics ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-ridgeback-rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.